ASCO 2024 | MelaRisk-001: validation of a 7-marker IHC assay in stage IB/IIA cutaneous melanoma

Teresa Amaral • 2 Jun 2024

ASCO 2024

Melanoma Skin Cancer

MelaRisk-001

Teresa Amaral, MD, PhD, University of Tübingen, Tübingen, Germany, discusses the multicenter MelaRisk-001 study (NCT05933577), which assessed a prognostic 7-marker immunohistochemistry (7-IHC) assay for stage IB/IIA cutaneous melanoma (CM). This study aims to identify high or low recurrence risk in patients using primary tumor assays involving immunohistochemistry (IHC) and gene expression profiling. These assays could be used with or without sentinel lymph node biopsy data. This is crucial as current adjuvant treatments are given without specific biomarkers, risking unnecessary toxicity and costs. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting or Advisory Role – CeCaVa; Delcath Systems; NeraCare GmbH; Novartis; Pierre Fabre
Research Funding – Agenus (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Biotech IOB (Inst); BMS GmbH & Co. KG (Inst); HUYA Bioscience International (Inst); Immunocore (Inst); MSD (Inst); NeraCare GmbH (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst); Skyline Diagnostics (Inst)